The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
ACADEMIA
1st CP Inhibitor Approved for Sarcoma, Could This Be a Breakthrough to Treatment of More Subtypes?
Last week, Japan approved an immune checkpoint (CP) inhibitor for sarcoma for the first time, with the label expansion of Tecentriq (atezolizumab) into alveolar soft part sarcoma (ASPS). Specialists believe this will be a major step forward in the treatment…
To read the full story
Related Article
- Moves Being Made to Resolve Japan’s Drug Lag in Sarcoma: Oncologist
February 25, 2025
- Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
ACADEMIA
- CGP Test Data for Over 100,000 Patients Now on National Database
May 13, 2025
- Diabetes Society Flags DKA Risk for AstraZeneca’s Truqap after Report of Death
April 21, 2025
- iPSC-Derived Cells Effective in Parkinson’s, Approval Could Come in FY2025
April 21, 2025
- Researchers Succeed in Transplanting iPS Cell Sheets for Type 1 Diabetes Patient
April 15, 2025
- NCCH Launches Pilot for Online Screening of Clinical Trial Participants
March 6, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…